JP2015531344A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531344A5
JP2015531344A5 JP2015530460A JP2015530460A JP2015531344A5 JP 2015531344 A5 JP2015531344 A5 JP 2015531344A5 JP 2015530460 A JP2015530460 A JP 2015530460A JP 2015530460 A JP2015530460 A JP 2015530460A JP 2015531344 A5 JP2015531344 A5 JP 2015531344A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
composition according
eye
semi
fluorinated alkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015530460A
Other languages
English (en)
Japanese (ja)
Other versions
JP6352266B2 (ja
JP2015531344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/068882 external-priority patent/WO2014041055A1/en
Publication of JP2015531344A publication Critical patent/JP2015531344A/ja
Publication of JP2015531344A5 publication Critical patent/JP2015531344A5/ja
Application granted granted Critical
Publication of JP6352266B2 publication Critical patent/JP6352266B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015530460A 2012-09-12 2013-09-12 半フッ化アルカンの混合物を含む組成物 Active JP6352266B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12183997.1 2012-09-12
EP12183997 2012-09-12
PCT/EP2013/068882 WO2014041055A1 (en) 2012-09-12 2013-09-12 Compositions comprising mixtures of semifluorinated alkanes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016124628A Division JP6253717B2 (ja) 2012-09-12 2016-06-23 半フッ化アルカンの混合物を含む組成物
JP2018034009A Division JP2018111704A (ja) 2012-09-12 2018-02-28 半フッ化アルカンの混合物を含む組成物

Publications (3)

Publication Number Publication Date
JP2015531344A JP2015531344A (ja) 2015-11-02
JP2015531344A5 true JP2015531344A5 (OSRAM) 2016-10-27
JP6352266B2 JP6352266B2 (ja) 2018-07-04

Family

ID=46832270

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015530460A Active JP6352266B2 (ja) 2012-09-12 2013-09-12 半フッ化アルカンの混合物を含む組成物
JP2016124628A Active JP6253717B2 (ja) 2012-09-12 2016-06-23 半フッ化アルカンの混合物を含む組成物
JP2018034009A Pending JP2018111704A (ja) 2012-09-12 2018-02-28 半フッ化アルカンの混合物を含む組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016124628A Active JP6253717B2 (ja) 2012-09-12 2016-06-23 半フッ化アルカンの混合物を含む組成物
JP2018034009A Pending JP2018111704A (ja) 2012-09-12 2018-02-28 半フッ化アルカンの混合物を含む組成物

Country Status (13)

Country Link
US (4) US10449164B2 (OSRAM)
EP (2) EP2895158B1 (OSRAM)
JP (3) JP6352266B2 (OSRAM)
KR (2) KR101874219B1 (OSRAM)
CN (7) CN113952321B (OSRAM)
AU (3) AU2013314370B2 (OSRAM)
BR (1) BR112015004997B1 (OSRAM)
CA (2) CA2883002C (OSRAM)
DE (1) DE202013012742U1 (OSRAM)
ES (2) ES2974663T3 (OSRAM)
MX (2) MX363182B (OSRAM)
MY (1) MY166228A (OSRAM)
WO (1) WO2014041055A1 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
ES2962524T3 (es) 2011-05-25 2024-03-19 Dermaliq Therapeutics Inc Composición farmacéutica tópica a base de alcanos semifluorados
AU2012260788B2 (en) 2011-05-25 2017-01-19 Dermaliq Therapeutics, Inc. Pharmaceutical composition for administration to nails
PL2806886T3 (pl) 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
PL2895144T3 (pl) 2012-09-12 2017-07-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów
CN113952321B (zh) 2012-09-12 2023-03-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
JP6642935B2 (ja) * 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
CN110403923B (zh) * 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN109640900B (zh) 2016-06-23 2020-07-07 诺瓦利克有限责任公司 一种试剂盒
KR102630701B1 (ko) * 2016-09-07 2024-01-29 글리아, 엘엘씨 두개 신경의 약리학적 피부 활성화에 의한 신경변성 질환과 관련된 증상의 치료
CN116172987A (zh) * 2016-09-22 2023-05-30 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
BR112019006194A2 (pt) * 2016-09-28 2019-06-18 Novaliq Gmbh composições que compreendem um ligante de ligação ao receptor de canabinóides
US10751295B2 (en) 2016-11-09 2020-08-25 Specialty Drug and Device, LLC Compositions and methods for the removal of ear wax
JP7032404B2 (ja) 2016-12-23 2022-03-08 ノバリック ゲーエムベーハー ドライアイ疾患の治療のための眼科用組成物
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
KR101895321B1 (ko) 2017-04-24 2018-09-05 주식회사 이루다 눈꺼풀의 분비샘 이상에 대한 치료장치
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
US20210069014A1 (en) 2017-05-06 2021-03-11 Novaliq Gmbh Drop dispenser
CN110650734B (zh) * 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
BR112020006072A2 (pt) 2017-09-27 2020-10-06 Novaliq Gmbh composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
JP2022500461A (ja) * 2018-09-22 2022-01-04 ノバリック ゲーエムベーハー 眼表面の損傷および乾燥の症状の治療のための眼科用組成物
PL3856128T3 (pl) 2018-09-27 2023-10-16 Dermaliq Therapeutics, Inc. Formulacja filtra przeciwsłonecznego do stosowania miejscowego
JP7360452B2 (ja) 2018-09-27 2023-10-12 ダーマリック セラピューティクス， インコーポレーテッド 脂質バリアの修復
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3886907B1 (en) * 2018-11-27 2024-10-02 Novaliq GmbH Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2022026805A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for removing meibum or inhibiting meibum buildup
CN116322646A (zh) * 2020-10-01 2023-06-23 阿比奥尼克斯制药公司 用于治疗眼病的包含基于脂质结合蛋白的复合物的组合物
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
KR20230142548A (ko) 2021-02-03 2023-10-11 에이디에스 테라퓨틱스 엘엘씨 국소 안과용 조성물
TW202327641A (zh) * 2021-09-14 2023-07-16 美商三葉草治療有限公司 使用經修飾之fgf-1多肽之治療方法

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPH0764702B2 (ja) 1986-04-23 1995-07-12 鐘紡株式会社 多相乳化型化粧料
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US5849291A (en) 1994-10-17 1998-12-15 Symbollon Corporation Opthalmic non-irritating iodine medicament
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (OSRAM) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6645963B2 (en) 1997-11-05 2003-11-11 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
EP0983037B1 (en) 1998-02-09 2003-05-02 MacroChem Corporation Antifungal nail lacquer
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
AU759641B2 (en) 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ES2261190T3 (es) 1999-02-08 2006-11-16 Alza Corporation Vehiculos viscosos no acuosos estables de fase unica y formulaciones que utilizan dichos vehiculos.
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US6576663B2 (en) 1999-12-22 2003-06-10 Alcon, Inc. 6-Keto prostaglandin F1α and analogs for treating dry eye
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
DE10051937C2 (de) 2000-10-19 2002-11-07 Infineon Technologies Ag Schaltungsanordnung zur Programmierung einer Verzögerungszeit eines Signalpfads
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
KR100757611B1 (ko) 2001-09-04 2007-09-10 트롬스도르프 게엠베하 운트 코. 카게 알츠나이미텔 손발톱 성장의 기능장애와 질환을 치료하기 위한 플라스터
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP3998596B2 (ja) 2003-03-31 2007-10-31 日本ペイント株式会社 塗膜ムラの算出式算出方法及び塗膜ムラの数値化方法
BRPI0412975A (pt) 2003-08-25 2006-10-03 Foamix Ltd espuma penetrante para uso farmacêutico
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
PT1670433E (pt) 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
US20050175541A1 (en) 2003-11-19 2005-08-11 Lanza Gregory M. Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2005099718A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
JP2008501806A (ja) 2004-06-08 2008-01-24 オキュラリス ファーマ， インコーポレイテッド 疎水性眼用組成物および使用方法
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
WO2007008666A2 (en) 2005-07-08 2007-01-18 Ocularis Pharma, Inc. Compositions and methods for improving vision using adherent thin films
JP2009503059A (ja) 2005-08-05 2009-01-29 ブハラット セルムズ アンド ヴァクシンズ リミテッド 防腐効果を有する静脈プロポフォールエマルジョン組成物
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20080050335A1 (en) 2006-07-25 2008-02-28 Osmotica Corp. Ophthalmic Solutions
CA2659775A1 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008060359A2 (en) 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
US9000048B2 (en) 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
EP2089282B1 (en) 2006-12-07 2014-01-08 Sun Pharma Advanced Research Company Ltd Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CA2711696C (en) 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
PT2110126E (pt) 2008-04-18 2012-02-20 Novaliq Gmbh Utilização inalativa e instilativa de alcanos semifluorados como veículos de substância activa na região intrapulmonar
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス，インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8669241B2 (en) 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
KR101759353B1 (ko) 2009-04-17 2017-07-18 나타크 파마 에스.엘 오메가-3 지방산이 풍부하고 피탄산 함량이 적은 조성물
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
US9012503B2 (en) 2009-06-25 2015-04-21 Lion Corporation Ophthalmic composition
JP5736635B2 (ja) * 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
DE102010027315A1 (de) 2009-07-24 2011-01-27 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Verfahren zur Entwicklung einer als Schaum auf die Haut zu applizierende flüssige Zusammensetzung sowie eine topisch applizierbare Zusammensetzung
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
TR201901309T4 (tr) 2011-01-04 2019-02-21 Novaliq Gmbh Semiflorlanmış alkanları içeren o/w emülsiyonları.
AU2012260788B2 (en) 2011-05-25 2017-01-19 Dermaliq Therapeutics, Inc. Pharmaceutical composition for administration to nails
ES2962524T3 (es) 2011-05-25 2024-03-19 Dermaliq Therapeutics Inc Composición farmacéutica tópica a base de alcanos semifluorados
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
PL2806886T3 (pl) 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
PL2895144T3 (pl) 2012-09-12 2017-07-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów
CN113952321B (zh) 2012-09-12 2023-03-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
EP2730291A1 (en) 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
US20140186350A1 (en) 2012-12-18 2014-07-03 Novartis Ag Compositions and methods for long acting molecules
BR112015021334B1 (pt) 2013-03-14 2020-04-07 Panoptica Inc formulação ocular tópica em suspenão e uso da mesma para tratamento e/ou melhora de uma doença do segmento posterior do olho
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
AU2014332488B2 (en) 2013-10-09 2017-03-09 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2015153469A1 (en) 2014-03-31 2015-10-08 Amcor Limited Controlled release container
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
US10123904B2 (en) 2014-08-13 2018-11-13 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
CN108601345A (zh) 2016-02-04 2018-09-28 戈登·韦恩·戴尔 用于损害cassie-baxter状态的方法
CN109640900B (zh) 2016-06-23 2020-07-07 诺瓦利克有限责任公司 一种试剂盒
CN116172987A (zh) 2016-09-22 2023-05-30 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
BR112019006194A2 (pt) 2016-09-28 2019-06-18 Novaliq Gmbh composições que compreendem um ligante de ligação ao receptor de canabinóides
CN110248657A (zh) 2016-12-22 2019-09-17 诺瓦利克有限责任公司 用于治疗眼内炎性眼病的包含他克莫司的组合物
JP7032404B2 (ja) 2016-12-23 2022-03-08 ノバリック ゲーエムベーハー ドライアイ疾患の治療のための眼科用組成物
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease

Similar Documents

Publication Publication Date Title
JP2015531344A5 (OSRAM)
JP2019534867A5 (OSRAM)
CN104619314B (zh) 包含半氟化烷烃的混合物的组合物
JP2016535777A5 (OSRAM)
CN103249403B (zh) 胡桐素及胡桐素衍生物和类似物的药物组合物及其制备方法
FI2887923T3 (fi) Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito
JP2018531233A5 (OSRAM)
PE20190738A1 (es) Formulacion novedosa para administracion por via oral
JP2019532931A5 (OSRAM)
JP2018021046A5 (OSRAM)
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
JP2018506570A5 (OSRAM)
JP2014129360A5 (OSRAM)
IL276888B2 (en) Pharmaceutical composition comprising timolol
JP2016511753A5 (OSRAM)
WO2017037593A3 (zh) 用于减少局部脂肪的医药组成物及其用途
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
JP2016027060A5 (OSRAM)
WO2013129322A1 (ja) 眼科用組成物
JP2015504860A5 (OSRAM)
JP5542059B2 (ja) Ｒｘｒ作動性物質を有効成分とする抗アレルギー剤
JP2019529408A5 (OSRAM)
JP2023126908A (ja) 眼科組成物
FI3302451T3 (fi) Palmitoyylietanoliamidia (pea) ja lykopeenia sisältävä yhdistelmä käytettäväksi inflammatoristen sairauksien hoidossa
JP2016538288A5 (OSRAM)